Memorial Sloan Kettering Commack

Commack, NY
(888) 828-2206

Sorting 10 by

Accepting patients

Stopping Maintenance Therapy

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
Learn more
  • Maintenance

Accepting patients

NUTRIVENTION-4

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 2
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Not yet accepting

Belantamab Mafodotin Combination Therapy

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1/2

Accepting patients

Talquetamab Consolidation After BCMA CAR-T

Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Post-CAR T
  • Phase 2

Accepting patients

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1

Accepting patients

Isatuximab After Allogeneic Stem Cell Transplant

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

Iberdomide vs. Observation Post Ide-Cel CAR-T

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
Learn more
  • CELMoD
  • Maintenance
  • Randomization
  • Phase 2

Accepting patients

Identifying Barriers to Cellular Therapy

Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD
Learn more
  • Observational Trial

Accepting patients

Genetic Studies

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Learn more

Accepting patients

Melphalan With or Without Siltuximab

Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
Learn more
  • Monoclonal Antibody
  • Interleukin 6 (IL-6)
  • Post-Autologous Stem Cell Transplant
  • Pre-Autologous Stem Cell Transplant
  • Phase 2